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Abstract
Introduction: We report a case of a 42-year-old man who had symptomatic hypothermia as a result of taking
olanzapine for paranoid schizophrenia. According to published data, only a few cases of hypothermia associated
with olanzapine have been reported since its introduction into clinical use.
Case presentation: A 42-year-old Sri Lankan man with schizophrenia who was being treated with a therapeutic
dose of olanzapine presented with reduced level of consciousness. He had a core temperature of 32°C and was
bradycardic. At the time of admission, the electrocardiogram showed sinus bradycardia with J waves. He did not
have any risk factors for developing hypothermia except the use of olanzapine. There was improvement in his
clinical condition with reversal of electrocardiogram changes following gradual rewarming and the omission of
olanzapine.
Conclusion: Hypothermia induced by antipsychotic medications is not uncommon, but olanzapine-induced
hypothermia is rare and occurrence has been reported during initiation or increasing the dose. But here the
patient developed hypothermia without dose adjustment.
Introduction
In homeothermic animals such as humans, body tem-
perature is maintained within a narrow range by the
hypothalamus. Hypothermia is traditionally defined as a
drop in core body temperature below 35°C (95°F).
In clinical practice, the most common causes of
hypothermia are prolonged exposure to cold temperature
as well as extremities of age, malnutrition, hypoglycemia,
adrenal insufficiency, hypothyroidism, diabetes mellitus,
stroke, disability, sepsis, shock, burns and exfoliative der-
matitis. After initial stimulation by hypothermia, there is
progressive depression of all organ systems. Depending
on the severity of the hypothermia, patients may show
various clinical manifestations from shivering and a feel-
ing of coldness to deep coma.
According to published data, only a few cases of
hypothermia associated with olanzapine have been
reported since its introduction into clinical use [1-5].
Temperature dysregulation is a known side effect of
antipsychotic medication through their effects on
hypothalamic neurotransmission. Recognized mechan-
isms include antagonism of the dopamine D2 [6] and
5-hydroxytryptamine 2 (5HT2) receptors [7-9]. Neuro-
tensin (NT) has also been recognized as a mediator of
hypothermia, especially in patients with schizophrenia
[10]. We report a similar case of hypothermia associated
with olanzapine use.
Case presentation
Our patient was a 42-year-old Sri Lankan man from a
mountainous region close to Kandy. The usual environ-
mental temperature of the patient’s hometown is around
30°C. He was unmarried and lived with his parents. He
was diagnosed with paranoid schizophrenia for the past
six years and was prescribed olanzapine 10 mg daily
since then. He did not have a history of diabetes melli-
tus, hypothyroidism, stroke, ischemic heart disease,
adrenal insufficiency, hypopituitarism or arthritis predis-
posing him to hypothermia.
He was admitted to our hospital because he was found
unresponsive in his room. He had been well the previous
* Correspondence: lrasnayake@gmail.com
Medical Unit, Teaching Hospital, Kandy, Sri Lanka
Rasnayake et al. Journal of Medical Case Reports 2011, 5:189
http://www.jmedicalcasereports.com/content/5/1/189 JOURNAL OF MEDICAL
CASE REPORTS
© 2011 Rasnayake et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.night. There was no history of substance ingestion, head
trauma or drug overdose. At presentation, his Glasgow
Coma Scale (GCS) score was 8/15. He opened his eyes to
pain and had no verbal response, but was able to localize
pain. His pulse rate was 48 beats/minute and regular
and was low in volume. His blood pressure was 90/60
mmHg. His muscle tone was reduced, and reflexes in all
four limbs were diminished with flexor plantar response.
His oral temperature was 32°C. At the time of admission,
his electrocardiogram (ECG) showed sinus bradycardia
with J waves (Figure 1).
His random venous plasma sugar was 130 mg/dL,
thyroid-stimulating hormone level was 2.2 mu/L and
free thyroxin level was 2.8 u/dL. The patient’sb l o o d
urea nitrogen was 5.5 mmol/L, Na was 135 mmol/L, K
was 4.4 mmol/L and complete blood count was normal.
His chest X-ray and contrast computed tomography of
the head were also unremarkable.
On the basis of the clinical findings, the patient’s body
temperature and ECG findings, the diagnosis of hypo-
thermia was made. The patient did not have any risk
factors for developing hypothermia except for the use of
olanzapine.
He was rewarmed gradually with blankets and warm
saline infusion. Olanzapine was discontinued. His level
of consciousness, vital signs and cardiac rhythm were
monitored. He gradually regained consciousness after
24 hours. After clinical improvement, the patient’s
body temperature was 38°C and the ECG changes had
reversed (Figure 2).
Discussion
Hypothermia in patients using antipsychotic drugs
(APD) is a serious, unpredictable, type B adverse drug
reaction and/or idiosyncratic reaction that frequently
leads to hospital and intensive care unit admission and
sometimes even to death.
According to published data in the World Health
Organization database, atypical antipsychotic medica-
tions are the commonest antipsychotics which cause
hypothermia. The commonest culprit is risperidone, and
the most common psychiatric disorder associated with
hypothermia is schizophrenia [11].
Antipsychotic medication-induced hypothermia could
be mediated through its effects on antagonism of D2
receptors [6] and may be due to antagonism of the
5-HT2 receptors [7-9]. Olanzapine is an atypical antipsy-
chotic which acts on both these receptors. Olanzapine is
structurally similar to clozapine, but is classified as a
thienobenzodizepine. Olanzapine has a higher affinity
for 5-HT2 serotonin receptors than D2 dopamine recep-
tors [11].
Like most atypical antipsychotics, compared to the
older typical ones, olanzapine has a lower affinity for
histamine, cholinergic muscarinic and a-adrenergic
receptors.
Blocking a2-adrenergic receptors (for example, chloro-
promazine, risperidone, clozapine, thioridazine) may also
increase the hypothermic effect by inhibiting peripheral
responses to cooling (that is, vasoconstriction and shi-
vering) [11].
In addition to these mechanisms, NT has been recog-
nized as a mediator of hypothermia. In schizophrenia,
thermal regulation is altered. This may be explained by
changes in NT levels. NT is one of the most important
thermoregulatory peptides that also play a role in the
antipsychotic actions of APDs. In patients with schizo-
phrenia, NT concentration int h ec e r e b r o s p i n a lf l u i d
(CSF) is low and is usually normalized following antipsy-
chotic drug use [10]. The hypothermic reaction is also
Figure 1 Electrocardiogram (ECG) obtained at the time of admission showing sinus bradycardia with J waves .
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APD administration at ambient temperatures below 22°
C led to hypothermia, whereas APD administration in a
room temperature of 29°C gave no thermal response
and at 32°C led to an increase in rectal temperature
[10,12]. Normally, a cold environment results in beha-
vior aimed at protection against the cold (for example,
taking extra blankets or clothes). APDs, however, induce
apathy and indifference, resulting in unawareness of
developing hypothermia.
There are only few reported cases of olanzapine-
induced hypothermia. In general, an antipsychotic medi-
cation can be the sole cause of hypothermia, or it can
be one of a number of possible causes coexisting in the
individual patient who develops hypothermia. In one
case, an older adult woman with schizophrenia but no
other medical illness developed hypothermia (31.7°C)
four hours after taking a single 10-mg dose of olanza-
pine [1]. She did not have any other medical illness pre-
disposing her to hypothermia and recovered after
discontinuation of olanzapine.
In another case, an 83-year-old woman with bipolar
affective disorder developed hypothermia of 33.1°C after
initiation of olanzapine 5 mg daily, but she was taking
lithium carbonate, clonazepam and trazodone as well.
Her body temperature was restored after cessation of all
medication [2].
In a third case, a 37-year-old woman with Prader-Willi
syndrome and psychotic disorder developed hypother-
mia on two occasions while being treated with risperi-
done and once following a single dose of olanzapine [3].
In this case, there were endocrine abnormalities as well
as infections that may have contributed to the develop-
ment of hypothermia. However, the patient had had
previous episodes of infections while she was not taking
antipsychotic medications and had not developed
hypothermia during those episodes.
In the fourth case, a 64-year-old woman with a 40-year
history of bipolar affective disorder developed hypo-
thermia while on olanzapine, but she had subclinical
hypothyroidism and type 2 diabetes mellitus, and in addi-
tion she was taking gabapentin [4]. These factors are
known to cause hypothermia. However, she improved
once olanzapine was discontinued and after levothyroxine
therapy was initiated.
In the fifth case, an adolescent with schizophreniform
disorder developed hypothermia and rhabdomyolysis
simultaneously after intramuscular injection of olanza-
pine. A 17-year-old boy was hospitalized for treatment
of psychotic symptoms, which persisted on risperidone
3 mg/day for three weeks. Then his antipsychotic drug
was shifted to oral olanzapine 10 mg/day. The next day
he received an intramuscular injection of olanzapine
5 mg and soon developed hypothermia, rhabdomyolysis,
Figure 2 ECG obtained after clinical improvement showing reversal of previous changes .
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gradually in the next two weeks after supportive treat-
ment was given [5].
In our patient, the general medical conditions predis-
posing them to the development of hypothermia, such as
hypoglycemia, adrenal insufficiency, diabetes mellitus,
shock, burns, exfoliative dermatitis, hypothyroidsm, mal-
nutrition and sepsis were not found. But it is shown in
the literature that schizophrenia per se is a risk factor for
hypothermia [10]. This could also have contributed to
hypothermia in our patient. Unlike our patient, who was
on olanzapine for six years without any recent dose
adjustment, previous case reports were associated with
either initiation or dose adjustment of APD. Furthermore,
there was no history of drug overdose in our patient. In
this case, there were no risk factors for the development
of hypothermia in the history, examination or investiga-
tions, other than the use of olanzapine and being a
patient with schizophrenia.
Conclusion
Hypothermia is a recognized complication of olanzapine,
but this case report raises the possibility of hypothermia
even in patients who are on stable doses of olanzapine
for a long period of time.
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Written informed consent was obtained from the patient
for publication of this case report and accompanying
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